13 recruiting, 10 completed, 4 unknown, 2 not yet recruiting. 16 Phase 1, 8 Phase 2, 3 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow Malignant Solid Tumors: new trials by email Literature Review of Malignant Solid Tumors trials Research Report on Malignant Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Diagnostic Efficacy of 177Lu-AF03 in Patients With Solid Tumors 177Lu-AF03 - Malignant Solid Tumors, Neoplasms | Early Phase 1 | Not yet recruiting | Yong He | 8 | 2026-10-20 | 2026-10-19 |
| CAIX-targeted PET/CT in Solid Tumors 68Ga-CAIX - Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma | Not applicable | Recruiting | Zhongnan Hospital | 100 | 2026-09-21 | 2026-10-13 |
| A Study of TAK-505 in Adults With Solid Tumors TAK-505 - Malignant Solid Tumors | Phase 1 / Phase 2 | Recruiting | Takeda | 151 | 2026-05-11 | 2026-10-28 |
| A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors SHR-7787 Injection, SHR-1316 Injection, SHR-4849 Injection - Malignant Solid Tumors | Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 400 | 2025-12-23 | 2026-01-12 |
| A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors SHR-4298 Injection - Malignant Solid Tumors | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 200 | 2025-12-03 | 2026-08-12 |
| Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting Medroxyprogesterone acetate oral suspension, high antiemetic regimen, moderate antiemetic regimen - Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | 126 | 2025-08-10 | 2025-08-15 |
| A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin - Malignant Solid Tumors | Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 120 | 2025-07-08 | 2026-03-03 |
| One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion - Malignant Solid Tumors | Phase 1 / Phase 2 | Recruiting | Immorna Biotherapeutics, Inc. | 72 | 2025-05-23 | 2026-11-05 |
| Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia Asciminib - Malignant Solid Tumors | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2025-02-14 | 2026-11-02 |
| A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors SHR-1681 - Malignant Solid Tumors | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 300 | 2025-01-21 | 2026-01-09 |
| The Effect of Serum Ferritin in irAE PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs - Immune-related Adverse Event, Malignant Solid Tumors | Not applicable | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 1500 | 2024-07-04 | 2024-11-25 |
| A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients T60c injection - Malignant Solid Tumors | Phase 1 / Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 62 | 2023-10-01 | 2023-10-13 |
| Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors 2.5-3.5mCi 64Cu-FAPI-XT117, 3.5-4.5mCi 64Cu-FAPI-XT117, 4.5-5.5mCi 64Cu-FAPI-XT117 - Malignant Solid Tumors | Phase 1 | Completed | The First Affiliated Hospital of Guangzhou Medical University | 15 | 2023-07-26 | 2023-12-26 |
| Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors JCXH-212 Injection - Malignant Solid Tumors | Early Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 24 | 2023-02-06 | 2024-05-14 |
| First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors 2-4 mCi 68Ga/64Cu-FAPI-XT117, 4-6 mCi 68Ga/64Cu-FAPI-XT117, 6-8 mCi 68Ga/64Cu-FAPI-XT117 - Malignant Solid Tumors | Phase 1 | Completed | Chinese PLA General Hospital | 14 | 2022-12-07 | 2023-12-20 |
| An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib Non-TKIs, Other TKIs, Regorafenib (Stivarga, BAY73- 4506) - Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19) | Completed | Bayer | 4103 | 2022-10-31 | 2023-11-07 | |
| A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors Sirolimus for Injection (Albumin-bound) - Malignant Solid Tumors | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 270 | 2022-10-01 | 2022-08-23 |
| Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors Genakumab - Malignant Solid Tumors | Phase 1 | Unknown | Changchun GeneScience Pharmaceutical Co., Ltd. | 120 | 2022-06-07 | 2022-07-06 |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors Malignant Solid Tumors, Other Neoplasms Solid Tumors | Recruiting | National Cancer Institute (NCI) | 10000 | 2019-01-28 | 2026-11-09 | |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas AZD5153, Olaparib - Malignant Solid Tumors, Lymphoma | Phase 1 | Completed | AstraZeneca | 49 | 2017-06-30 | 2021-05-06 |
Showing 20 of 29. Sign in to see all of them.
Breast Neoplasms (2) · Colonic Neoplasms (2) · Lymphoma (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Ovarian Neoplasms (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Colonic Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Male Urogenital Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
olaparib (2) · AZD5153 (1) · Antibodies (1) · Antineoplastic Agents (1) · Carboplatin (1) · Cisplatin (1) · Etoposide (1) · Immune Checkpoint Inhibitors (1) · Injections (1) · SAR125844 (1) · Sirolimus (1) · Sorafenib (1) · Topotecan (1) · asciminib (1) · pegfilgrastim (1)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3) · AstraZeneca (2) · National Cancer Institute (NCI) (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Baxalta now part of Shire (1) · Bayer (1) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Chinese PLA General Hospital (1) · Immorna Biotherapeutics, Inc. (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · N.N. Petrov National Medical Research Center of Oncology (1)
China (14) · United States (9) · Germany (2) · Canada (1) · France (1) · Italy (1) · Russia (1) · Spain (1) · United Kingdom (1)
Christoph Schliemann, Prof. (1) · Erika P Hamilton, MD (1) · Ghayas Issa, MD (1) · Irina Baldueva, MD, PhD, DSc (1) · James Carmichael, BSc MBChB MD FRCP (1) · James Cassidy (1) · James L Gulley, M.D. (1) · Kayvan Keshari, PhD (1) · Mary F Wedekind Malone, D.O. (1) · RuiHua Xu (1) · Ruimin Wang (1) · Xiangdong Cheng (1) · Xiubao Ren, M.D, Ph.D (1)
PMID 26130065, PMID 26596767, PMID 29145039, PMID 31564440, PMID 32207164, PMID 32517329
2016 (1)